1	1	_	_	_	_	_	_	_	_
2	.	_	_	_	_	_	_	_	_


1	Introduction	_	_	_	_	_	_	_	_


1	Cholesterol	_	_	_	_	_	_	_	_
2	is	_	_	_	_	_	_	_	_
3	predominantly	_	_	_	_	_	_	_	_
4	synthesized	_	_	_	_	_	_	_	_
5	de	_	_	_	_	_	_	_	_
6	novo	_	_	_	_	_	_	_	_
7	in	_	_	_	_	_	_	_	_
8	the	_	_	_	_	_	_	_	_
9	liver	_	_	_	_	_	_	_	_
10	with	_	_	_	_	_	_	_	_
11	lesser	_	_	_	_	_	_	_	_
12	amounts	_	_	_	_	_	_	_	_
13	obtained	_	_	_	_	_	_	_	_
14	from	_	_	_	_	_	_	_	_
15	the	_	_	_	_	_	_	_	_
16	diet	_	_	_	_	_	_	_	_
17	.	_	_	_	_	_	_	_	_


1	Dietary	_	_	_	_	_	_	_	_
2	intake	_	_	_	_	_	_	_	_
3	,	_	_	_	_	_	_	_	_
4	de	_	_	_	_	_	_	_	_
5	novo	_	_	_	_	_	_	_	_
6	synthesis	_	_	_	_	_	_	_	_
7	,	_	_	_	_	_	_	_	_
8	metabolism	_	_	_	_	_	_	_	_
9	and	_	_	_	_	_	_	_	_
10	excretion	_	_	_	_	_	_	_	_
11	,	_	_	_	_	_	_	_	_
12	combine	_	_	_	_	_	_	_	_
13	to	_	_	_	_	_	_	_	_
14	balance	_	_	_	_	_	_	_	_
15	circulating	_	_	_	_	_	_	_	_
16	cholesterol	_	_	_	_	_	_	_	_
17	levels	_	_	_	_	_	_	_	_
18	ensuring	_	_	_	_	_	_	_	_
19	extra-hepatic	_	_	_	_	_	_	_	_
20	tissues	_	_	_	_	_	_	_	_
21	are	_	_	_	_	_	_	_	_
22	sufficiently	_	_	_	_	_	_	_	_
23	equipped	_	_	_	_	_	_	_	_
24	to	_	_	_	_	_	_	_	_
25	produce	_	_	_	_	_	_	_	_
26	a	_	_	_	_	_	_	_	_
27	range	_	_	_	_	_	_	_	_
28	of	_	_	_	_	_	_	_	_
29	metabolites	_	_	_	_	_	_	_	_
30	including	_	_	_	_	_	_	_	_
31	steroid	_	_	_	_	_	_	_	_
32	hormones	_	_	_	_	_	_	_	_
33	,	_	_	_	_	_	_	_	_
34	bile	_	_	_	_	_	_	_	_
35	acids	_	_	_	_	_	_	_	_
36	and	_	_	_	_	_	_	_	_
37	seco-steroids	_	_	_	_	_	_	_	_
38	.	_	_	_	_	_	_	_	_


1	Side-chain	_	_	_	_	_	_	_	_
2	hydroxycholesterols	_	_	_	_	_	_	_	_
3	(	_	_	_	_	_	_	_	_
4	scOHCs	_	_	_	_	_	_	_	_
5	)	_	_	_	_	_	_	_	_
6	are	_	_	_	_	_	_	_	_
7	typically	_	_	_	_	_	_	_	_
8	formed	_	_	_	_	_	_	_	_
9	through	_	_	_	_	_	_	_	_
10	hydroxylation	_	_	_	_	_	_	_	_
11	of	_	_	_	_	_	_	_	_
12	cholesterol	_	_	_	_	_	_	_	_
13	by	_	_	_	_	_	_	_	_
14	specialized	_	_	_	_	_	_	_	_
15	members	_	_	_	_	_	_	_	_
16	of	_	_	_	_	_	_	_	_
17	the	_	_	_	_	_	_	_	_
18	Cytochrome	_	_	_	_	_	_	_	_
19	P450	_	_	_	_	_	_	_	_
20	family	_	_	_	_	_	_	_	_
21	,	_	_	_	_	_	_	_	_
22	which	_	_	_	_	_	_	_	_
23	bind	_	_	_	_	_	_	_	_
24	and	_	_	_	_	_	_	_	_
25	activate	_	_	_	_	_	_	_	_
26	the	_	_	_	_	_	_	_	_
27	Liver	_	_	_	_	_	_	_	_
28	X	_	_	_	_	_	_	_	_
29	Receptor-alpha	_	_	_	_	_	_	_	_
30	(	_	_	_	_	_	_	_	_
31	LXRA	_	_	_	_	_	_	_	_
32	;	_	_	_	_	_	_	_	_
33	gene	_	_	_	_	_	_	_	_
34	name	_	_	_	_	_	_	_	_
35	NR1H3	_	_	_	_	_	_	_	_
36	)	_	_	_	_	_	_	_	_
37	and	_	_	_	_	_	_	_	_
38	beta	_	_	_	_	_	_	_	_
39	(	_	_	_	_	_	_	_	_
40	LXRB	_	_	_	_	_	_	_	_
41	;	_	_	_	_	_	_	_	_
42	gene	_	_	_	_	_	_	_	_
43	name	_	_	_	_	_	_	_	_
44	NR1H2	_	_	_	_	_	_	_	_
45	)	_	_	_	_	_	_	_	_
46	transcription	_	_	_	_	_	_	_	_
47	factors	_	_	_	_	_	_	_	_
48	.	_	_	_	_	_	_	_	_


1	LXR	_	_	_	_	_	_	_	_
2	target	_	_	_	_	_	_	_	_
3	genes	_	_	_	_	_	_	_	_
4	are	_	_	_	_	_	_	_	_
5	typically	_	_	_	_	_	_	_	_
6	involved	_	_	_	_	_	_	_	_
7	in	_	_	_	_	_	_	_	_
8	cholesterol	_	_	_	_	_	_	_	_
9	and	_	_	_	_	_	_	_	_
10	fatty	_	_	_	_	_	_	_	_
11	acid	_	_	_	_	_	_	_	_
12	metabolism	_	_	_	_	_	_	_	_
13	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	normal	_	_	_	_	_	_	_	_
3	tissue	_	_	_	_	_	_	_	_
4	,	_	_	_	_	_	_	_	_
5	expression	_	_	_	_	_	_	_	_
6	of	_	_	_	_	_	_	_	_
7	LXRA	_	_	_	_	_	_	_	_
8	is	_	_	_	_	_	_	_	_
9	inducible	_	_	_	_	_	_	_	_
10	in	_	_	_	_	_	_	_	_
11	the	_	_	_	_	_	_	_	_
12	liver	_	_	_	_	_	_	_	_
13	,	_	_	_	_	_	_	_	_
14	intestine	_	_	_	_	_	_	_	_
15	,	_	_	_	_	_	_	_	_
16	macrophages	_	_	_	_	_	_	_	_
17	and	_	_	_	_	_	_	_	_
18	adipocytes	_	_	_	_	_	_	_	_
19	,	_	_	_	_	_	_	_	_
20	whilst	_	_	_	_	_	_	_	_
21	expression	_	_	_	_	_	_	_	_
22	of	_	_	_	_	_	_	_	_
23	LXRB	_	_	_	_	_	_	_	_
24	is	_	_	_	_	_	_	_	_
25	more	_	_	_	_	_	_	_	_
26	ubiquitous	_	_	_	_	_	_	_	_
27	.	_	_	_	_	_	_	_	_


1	As	_	_	_	_	_	_	_	_
2	well	_	_	_	_	_	_	_	_
3	as	_	_	_	_	_	_	_	_
4	differences	_	_	_	_	_	_	_	_
5	in	_	_	_	_	_	_	_	_
6	expression	_	_	_	_	_	_	_	_
7	of	_	_	_	_	_	_	_	_
8	LXRA	_	_	_	_	_	_	_	_
9	and	_	_	_	_	_	_	_	_
10	LXRB	_	_	_	_	_	_	_	_
11	,	_	_	_	_	_	_	_	_
12	local	_	_	_	_	_	_	_	_
13	concentrations	_	_	_	_	_	_	_	_
14	of	_	_	_	_	_	_	_	_
15	the	_	_	_	_	_	_	_	_
16	scOHCs	_	_	_	_	_	_	_	_
17	differ	_	_	_	_	_	_	_	_
18	considerably	_	_	_	_	_	_	_	_
19	between	_	_	_	_	_	_	_	_
20	tissues	_	_	_	_	_	_	_	_
21	,	_	_	_	_	_	_	_	_
22	and	_	_	_	_	_	_	_	_
23	relative	_	_	_	_	_	_	_	_
24	to	_	_	_	_	_	_	_	_
25	each	_	_	_	_	_	_	_	_
26	other	_	_	_	_	_	_	_	_
27	,	_	_	_	_	_	_	_	_
28	sometimes	_	_	_	_	_	_	_	_
29	by	_	_	_	_	_	_	_	_
30	as	_	_	_	_	_	_	_	_
31	much	_	_	_	_	_	_	_	_
32	as	_	_	_	_	_	_	_	_
33	1000-fold	_	_	_	_	_	_	_	_
34	and	_	_	_	_	_	_	_	_
35	variance	_	_	_	_	_	_	_	_
36	can	_	_	_	_	_	_	_	_
37	also	_	_	_	_	_	_	_	_
38	depend	_	_	_	_	_	_	_	_
39	on	_	_	_	_	_	_	_	_
40	disease	_	_	_	_	_	_	_	_
41	status	_	_	_	_	_	_	_	_
42	.	_	_	_	_	_	_	_	_


1	Furthermore	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	the	_	_	_	_	_	_	_	_
4	different	_	_	_	_	_	_	_	_
5	scOHCs	_	_	_	_	_	_	_	_
6	have	_	_	_	_	_	_	_	_
7	varying	_	_	_	_	_	_	_	_
8	capacities	_	_	_	_	_	_	_	_
9	to	_	_	_	_	_	_	_	_
10	activate	_	_	_	_	_	_	_	_
11	LXR-mediated	_	_	_	_	_	_	_	_
12	transcription	_	_	_	_	_	_	_	_
13	,	_	_	_	_	_	_	_	_
14	imposing	_	_	_	_	_	_	_	_
15	an	_	_	_	_	_	_	_	_
16	element	_	_	_	_	_	_	_	_
17	of	_	_	_	_	_	_	_	_
18	selective	_	_	_	_	_	_	_	_
19	modulation	_	_	_	_	_	_	_	_
20	onto	_	_	_	_	_	_	_	_
21	signalling	_	_	_	_	_	_	_	_
22	.	_	_	_	_	_	_	_	_


1	26-OHC	_	_	_	_	_	_	_	_
2	(	_	_	_	_	_	_	_	_
3	commonly	_	_	_	_	_	_	_	_
4	referred	_	_	_	_	_	_	_	_
5	to	_	_	_	_	_	_	_	_
6	as	_	_	_	_	_	_	_	_
7	27-OHC	_	_	_	_	_	_	_	_
8	)	_	_	_	_	_	_	_	_
9	for	_	_	_	_	_	_	_	_
10	example	_	_	_	_	_	_	_	_
11	is	_	_	_	_	_	_	_	_
12	the	_	_	_	_	_	_	_	_
13	most	_	_	_	_	_	_	_	_
14	abundant	_	_	_	_	_	_	_	_
15	scOHC	_	_	_	_	_	_	_	_
16	,	_	_	_	_	_	_	_	_
17	but	_	_	_	_	_	_	_	_
18	is	_	_	_	_	_	_	_	_
19	a	_	_	_	_	_	_	_	_
20	relatively	_	_	_	_	_	_	_	_
21	weak	_	_	_	_	_	_	_	_
22	LXR	_	_	_	_	_	_	_	_
23	agonist	_	_	_	_	_	_	_	_
24	.	_	_	_	_	_	_	_	_


1	Moreover	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	there	_	_	_	_	_	_	_	_
4	is	_	_	_	_	_	_	_	_
5	little	_	_	_	_	_	_	_	_
6	difference	_	_	_	_	_	_	_	_
7	in	_	_	_	_	_	_	_	_
8	scOHC	_	_	_	_	_	_	_	_
9	concentrations	_	_	_	_	_	_	_	_
10	between	_	_	_	_	_	_	_	_
11	breast	_	_	_	_	_	_	_	_
12	cancer	_	_	_	_	_	_	_	_
13	subtypes	_	_	_	_	_	_	_	_
14	.	_	_	_	_	_	_	_	_


1	Transcriptional	_	_	_	_	_	_	_	_
2	activity	_	_	_	_	_	_	_	_
3	of	_	_	_	_	_	_	_	_
4	the	_	_	_	_	_	_	_	_
5	LXRs	_	_	_	_	_	_	_	_
6	,	_	_	_	_	_	_	_	_
7	like	_	_	_	_	_	_	_	_
8	the	_	_	_	_	_	_	_	_
9	other	_	_	_	_	_	_	_	_
10	members	_	_	_	_	_	_	_	_
11	of	_	_	_	_	_	_	_	_
12	the	_	_	_	_	_	_	_	_
13	Nuclear	_	_	_	_	_	_	_	_
14	Receptor	_	_	_	_	_	_	_	_
15	(	_	_	_	_	_	_	_	_
16	NR	_	_	_	_	_	_	_	_
17	)	_	_	_	_	_	_	_	_
18	superfamily	_	_	_	_	_	_	_	_
19	,	_	_	_	_	_	_	_	_
20	is	_	_	_	_	_	_	_	_
21	not	_	_	_	_	_	_	_	_
22	just	_	_	_	_	_	_	_	_
23	regulated	_	_	_	_	_	_	_	_
24	by	_	_	_	_	_	_	_	_
25	ligand	_	_	_	_	_	_	_	_
26	bioavailability	_	_	_	_	_	_	_	_
27	;	_	_	_	_	_	_	_	_
28	chromatin	_	_	_	_	_	_	_	_
29	environment	_	_	_	_	_	_	_	_
30	,	_	_	_	_	_	_	_	_
31	cross-talk	_	_	_	_	_	_	_	_
32	and	_	_	_	_	_	_	_	_
33	competition	_	_	_	_	_	_	_	_
34	for	_	_	_	_	_	_	_	_
35	response	_	_	_	_	_	_	_	_
36	element	_	_	_	_	_	_	_	_
37	binding	_	_	_	_	_	_	_	_
38	with	_	_	_	_	_	_	_	_
39	other	_	_	_	_	_	_	_	_
40	NRs	_	_	_	_	_	_	_	_
41	,	_	_	_	_	_	_	_	_
42	as	_	_	_	_	_	_	_	_
43	well	_	_	_	_	_	_	_	_
44	as	_	_	_	_	_	_	_	_
45	cell-	_	_	_	_	_	_	_	_
46	and	_	_	_	_	_	_	_	_
47	tissue-type	_	_	_	_	_	_	_	_
48	dependent	_	_	_	_	_	_	_	_
49	expression	_	_	_	_	_	_	_	_
50	of	_	_	_	_	_	_	_	_
51	cofactors	_	_	_	_	_	_	_	_
52	are	_	_	_	_	_	_	_	_
53	also	_	_	_	_	_	_	_	_
54	key	_	_	_	_	_	_	_	_
55	mediators	_	_	_	_	_	_	_	_
56	.	_	_	_	_	_	_	_	_


1	For	_	_	_	_	_	_	_	_
2	example	_	_	_	_	_	_	_	_
3	,	_	_	_	_	_	_	_	_
4	the	_	_	_	_	_	_	_	_
5	expression	_	_	_	_	_	_	_	_
6	of	_	_	_	_	_	_	_	_
7	corepressors	_	_	_	_	_	_	_	_
8	such	_	_	_	_	_	_	_	_
9	as	_	_	_	_	_	_	_	_
10	NCOR1	_	_	_	_	_	_	_	_
11	and	_	_	_	_	_	_	_	_
12	NCOR2/SMRT	_	_	_	_	_	_	_	_
13	determine	_	_	_	_	_	_	_	_
14	how	_	_	_	_	_	_	_	_
15	several	_	_	_	_	_	_	_	_
16	cancers	_	_	_	_	_	_	_	_
17	respond	_	_	_	_	_	_	_	_
18	to	_	_	_	_	_	_	_	_
19	nutritive	_	_	_	_	_	_	_	_
20	ligands	_	_	_	_	_	_	_	_
21	.	_	_	_	_	_	_	_	_


1	LXRA	_	_	_	_	_	_	_	_
2	has	_	_	_	_	_	_	_	_
3	a	_	_	_	_	_	_	_	_
4	100-fold	_	_	_	_	_	_	_	_
5	higher	_	_	_	_	_	_	_	_
6	binding	_	_	_	_	_	_	_	_
7	affinity	_	_	_	_	_	_	_	_
8	than	_	_	_	_	_	_	_	_
9	LXRB	_	_	_	_	_	_	_	_
10	for	_	_	_	_	_	_	_	_
11	the	_	_	_	_	_	_	_	_
12	corepressors	_	_	_	_	_	_	_	_
13	NCOR1	_	_	_	_	_	_	_	_
14	and	_	_	_	_	_	_	_	_
15	NCOR2	_	_	_	_	_	_	_	_
16	and	_	_	_	_	_	_	_	_
17	deregulation	_	_	_	_	_	_	_	_
18	of	_	_	_	_	_	_	_	_
19	these	_	_	_	_	_	_	_	_
20	corepressors	_	_	_	_	_	_	_	_
21	allows	_	_	_	_	_	_	_	_
22	prostate	_	_	_	_	_	_	_	_
23	and	_	_	_	_	_	_	_	_
24	bladder	_	_	_	_	_	_	_	_
25	cancer	_	_	_	_	_	_	_	_
26	cells	_	_	_	_	_	_	_	_
27	to	_	_	_	_	_	_	_	_
28	evade	_	_	_	_	_	_	_	_
29	cancer	_	_	_	_	_	_	_	_
30	suppressive	_	_	_	_	_	_	_	_
31	signals	_	_	_	_	_	_	_	_
32	of	_	_	_	_	_	_	_	_
33	Vitamin	_	_	_	_	_	_	_	_
34	D	_	_	_	_	_	_	_	_
35	(	_	_	_	_	_	_	_	_
36	through	_	_	_	_	_	_	_	_
37	repression	_	_	_	_	_	_	_	_
38	of	_	_	_	_	_	_	_	_
39	Vitamin	_	_	_	_	_	_	_	_
40	D	_	_	_	_	_	_	_	_
41	Receptor	_	_	_	_	_	_	_	_
42	(	_	_	_	_	_	_	_	_
43	VDR	_	_	_	_	_	_	_	_
44	)	_	_	_	_	_	_	_	_
45	)	_	_	_	_	_	_	_	_
46	and	_	_	_	_	_	_	_	_
47	omega-3	_	_	_	_	_	_	_	_
48	fatty	_	_	_	_	_	_	_	_
49	acids	_	_	_	_	_	_	_	_
50	(	_	_	_	_	_	_	_	_
51	through	_	_	_	_	_	_	_	_
52	repression	_	_	_	_	_	_	_	_
53	of	_	_	_	_	_	_	_	_
54	peroxisome	_	_	_	_	_	_	_	_
55	proliferator-activated	_	_	_	_	_	_	_	_
56	receptors	_	_	_	_	_	_	_	_
57	(	_	_	_	_	_	_	_	_
58	PPARs	_	_	_	_	_	_	_	_
59	)	_	_	_	_	_	_	_	_
60	)	_	_	_	_	_	_	_	_
61	by	_	_	_	_	_	_	_	_
62	impairing	_	_	_	_	_	_	_	_
63	sensitivity	_	_	_	_	_	_	_	_
64	to	_	_	_	_	_	_	_	_
65	ligand	_	_	_	_	_	_	_	_
66	.	_	_	_	_	_	_	_	_


1	Simply	_	_	_	_	_	_	_	_
2	measuring	_	_	_	_	_	_	_	_
3	scOHC	_	_	_	_	_	_	_	_
4	concentrations	_	_	_	_	_	_	_	_
5	does	_	_	_	_	_	_	_	_
6	not	_	_	_	_	_	_	_	_
7	sufficiently	_	_	_	_	_	_	_	_
8	determine	_	_	_	_	_	_	_	_
9	their	_	_	_	_	_	_	_	_
10	contributions	_	_	_	_	_	_	_	_
11	to	_	_	_	_	_	_	_	_
12	LXR	_	_	_	_	_	_	_	_
13	signalling	_	_	_	_	_	_	_	_
14	;	_	_	_	_	_	_	_	_
15	concentration	_	_	_	_	_	_	_	_
16	and	_	_	_	_	_	_	_	_
17	activation	_	_	_	_	_	_	_	_
18	potential	_	_	_	_	_	_	_	_
19	should	_	_	_	_	_	_	_	_
20	be	_	_	_	_	_	_	_	_
21	assessed	_	_	_	_	_	_	_	_
22	in	_	_	_	_	_	_	_	_
23	combination	_	_	_	_	_	_	_	_
24	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	cancer	_	_	_	_	_	_	_	_
3	,	_	_	_	_	_	_	_	_
4	the	_	_	_	_	_	_	_	_
5	function	_	_	_	_	_	_	_	_
6	of	_	_	_	_	_	_	_	_
7	the	_	_	_	_	_	_	_	_
8	scOHC-LXR	_	_	_	_	_	_	_	_
9	signalling	_	_	_	_	_	_	_	_
10	axis	_	_	_	_	_	_	_	_
11	appears	_	_	_	_	_	_	_	_
12	site	_	_	_	_	_	_	_	_
13	specific	_	_	_	_	_	_	_	_
14	as	_	_	_	_	_	_	_	_
15	both	_	_	_	_	_	_	_	_
16	tumour	_	_	_	_	_	_	_	_
17	suppressive	_	_	_	_	_	_	_	_
18	and	_	_	_	_	_	_	_	_
19	promoting	_	_	_	_	_	_	_	_
20	roles	_	_	_	_	_	_	_	_
21	have	_	_	_	_	_	_	_	_
22	been	_	_	_	_	_	_	_	_
23	described	_	_	_	_	_	_	_	_
24	.	_	_	_	_	_	_	_	_


1	For	_	_	_	_	_	_	_	_
2	example	_	_	_	_	_	_	_	_
3	,	_	_	_	_	_	_	_	_
4	scOHC-LXR	_	_	_	_	_	_	_	_
5	signalling	_	_	_	_	_	_	_	_
6	impairs	_	_	_	_	_	_	_	_
7	invasion	_	_	_	_	_	_	_	_
8	and	_	_	_	_	_	_	_	_
9	angiogenesis	_	_	_	_	_	_	_	_
10	in	_	_	_	_	_	_	_	_
11	melanoma	_	_	_	_	_	_	_	_
12	and	_	_	_	_	_	_	_	_
13	is	_	_	_	_	_	_	_	_
14	anti-proliferative	_	_	_	_	_	_	_	_
15	in	_	_	_	_	_	_	_	_
16	lung	_	_	_	_	_	_	_	_
17	cancer	_	_	_	_	_	_	_	_
18	in	_	_	_	_	_	_	_	_
19	vivo	_	_	_	_	_	_	_	_
20	,	_	_	_	_	_	_	_	_
21	as	_	_	_	_	_	_	_	_
22	it	_	_	_	_	_	_	_	_
23	is	_	_	_	_	_	_	_	_
24	in	_	_	_	_	_	_	_	_
25	almost	_	_	_	_	_	_	_	_
26	every	_	_	_	_	_	_	_	_
27	cancer	_	_	_	_	_	_	_	_
28	cell	_	_	_	_	_	_	_	_
29	line	_	_	_	_	_	_	_	_
30	studied	_	_	_	_	_	_	_	_
31	in	_	_	_	_	_	_	_	_
32	vitro	_	_	_	_	_	_	_	_
33	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	Oestrogen	_	_	_	_	_	_	_	_
3	Receptor	_	_	_	_	_	_	_	_
4	(	_	_	_	_	_	_	_	_
5	ER)-positive	_	_	_	_	_	_	_	_
6	Breast	_	_	_	_	_	_	_	_
7	Cancer	_	_	_	_	_	_	_	_
8	(	_	_	_	_	_	_	_	_
9	BCa	_	_	_	_	_	_	_	_
10	)	_	_	_	_	_	_	_	_
11	however	_	_	_	_	_	_	_	_
12	26-OHC	_	_	_	_	_	_	_	_
13	promotes	_	_	_	_	_	_	_	_
14	growth	_	_	_	_	_	_	_	_
15	in	_	_	_	_	_	_	_	_
16	vivo	_	_	_	_	_	_	_	_
17	via	_	_	_	_	_	_	_	_
18	ER-alpha	_	_	_	_	_	_	_	_
19	.	_	_	_	_	_	_	_	_


1	In	_	_	_	_	_	_	_	_
2	ER-negative	_	_	_	_	_	_	_	_
3	BCa	_	_	_	_	_	_	_	_
4	26-OHC	_	_	_	_	_	_	_	_
5	drives	_	_	_	_	_	_	_	_
6	the	_	_	_	_	_	_	_	_
7	epithelial-to-mesenchymal	_	_	_	_	_	_	_	_
8	transition	_	_	_	_	_	_	_	_
9	and	_	_	_	_	_	_	_	_
10	promotes	_	_	_	_	_	_	_	_
11	colonization	_	_	_	_	_	_	_	_
12	of	_	_	_	_	_	_	_	_
13	metastatic	_	_	_	_	_	_	_	_
14	sites	_	_	_	_	_	_	_	_
15	in	_	_	_	_	_	_	_	_
16	through	_	_	_	_	_	_	_	_
17	mobilization	_	_	_	_	_	_	_	_
18	of	_	_	_	_	_	_	_	_
19	γδ-T	_	_	_	_	_	_	_	_
20	cells	_	_	_	_	_	_	_	_
21	.	_	_	_	_	_	_	_	_


1	Furthermore	_	_	_	_	_	_	_	_
2	,	_	_	_	_	_	_	_	_
3	concentrations	_	_	_	_	_	_	_	_
4	of	_	_	_	_	_	_	_	_
5	several	_	_	_	_	_	_	_	_
6	scOHCs	_	_	_	_	_	_	_	_
7	are	_	_	_	_	_	_	_	_
8	altered	_	_	_	_	_	_	_	_
9	in	_	_	_	_	_	_	_	_
10	BCa	_	_	_	_	_	_	_	_
11	relative	_	_	_	_	_	_	_	_
12	to	_	_	_	_	_	_	_	_
13	normal	_	_	_	_	_	_	_	_
14	tissue	_	_	_	_	_	_	_	_
15	,	_	_	_	_	_	_	_	_
16	and	_	_	_	_	_	_	_	_
17	25-OHC	_	_	_	_	_	_	_	_
18	is	_	_	_	_	_	_	_	_
19	elevated	_	_	_	_	_	_	_	_
20	in	_	_	_	_	_	_	_	_
21	the	_	_	_	_	_	_	_	_
22	circulation	_	_	_	_	_	_	_	_
23	of	_	_	_	_	_	_	_	_
24	BCa	_	_	_	_	_	_	_	_
25	patients	_	_	_	_	_	_	_	_
26	who	_	_	_	_	_	_	_	_
27	have	_	_	_	_	_	_	_	_
28	relapsed	_	_	_	_	_	_	_	_
29	compared	_	_	_	_	_	_	_	_
30	to	_	_	_	_	_	_	_	_
31	those	_	_	_	_	_	_	_	_
32	with	_	_	_	_	_	_	_	_
33	primary	_	_	_	_	_	_	_	_
34	disease	_	_	_	_	_	_	_	_
35	.	_	_	_	_	_	_	_	_


1	We	_	_	_	_	_	_	_	_
2	recently	_	_	_	_	_	_	_	_
3	evaluated	_	_	_	_	_	_	_	_
4	LXR	_	_	_	_	_	_	_	_
5	ligand	_	_	_	_	_	_	_	_
6	bio-availability	_	_	_	_	_	_	_	_
7	in	_	_	_	_	_	_	_	_
8	a	_	_	_	_	_	_	_	_
9	small	_	_	_	_	_	_	_	_
10	BCa	_	_	_	_	_	_	_	_
11	cohort	_	_	_	_	_	_	_	_
12	and	_	_	_	_	_	_	_	_
13	found	_	_	_	_	_	_	_	_
14	large	_	_	_	_	_	_	_	_
15	inter	_	_	_	_	_	_	_	_
16	tumoural	_	_	_	_	_	_	_	_
17	heterogeneity	_	_	_	_	_	_	_	_
18	in	_	_	_	_	_	_	_	_
19	oxysterol	_	_	_	_	_	_	_	_
20	content	_	_	_	_	_	_	_	_
21	,	_	_	_	_	_	_	_	_
22	but	_	_	_	_	_	_	_	_
23	no	_	_	_	_	_	_	_	_
24	difference	_	_	_	_	_	_	_	_
25	in	_	_	_	_	_	_	_	_
26	ligand	_	_	_	_	_	_	_	_
27	concentrations	_	_	_	_	_	_	_	_
28	between	_	_	_	_	_	_	_	_
29	tumour	_	_	_	_	_	_	_	_
30	subtypes	_	_	_	_	_	_	_	_
31	.	_	_	_	_	_	_	_	_


1	Systematic	_	_	_	_	_	_	_	_
2	evaluation	_	_	_	_	_	_	_	_
3	of	_	_	_	_	_	_	_	_
4	scOHC	_	_	_	_	_	_	_	_
5	bioavailability	_	_	_	_	_	_	_	_
6	and	_	_	_	_	_	_	_	_
7	activation	_	_	_	_	_	_	_	_
8	potential	_	_	_	_	_	_	_	_
9	,	_	_	_	_	_	_	_	_
10	coupled	_	_	_	_	_	_	_	_
11	with	_	_	_	_	_	_	_	_
12	analysis	_	_	_	_	_	_	_	_
13	of	_	_	_	_	_	_	_	_
14	NR	_	_	_	_	_	_	_	_
15	cofactor	_	_	_	_	_	_	_	_
16	expression	_	_	_	_	_	_	_	_
17	between	_	_	_	_	_	_	_	_
18	BCa	_	_	_	_	_	_	_	_
19	subtypes	_	_	_	_	_	_	_	_
20	has	_	_	_	_	_	_	_	_
21	not	_	_	_	_	_	_	_	_
22	been	_	_	_	_	_	_	_	_
23	performed	_	_	_	_	_	_	_	_
24	previously	_	_	_	_	_	_	_	_
25	.	_	_	_	_	_	_	_	_


1	Given	_	_	_	_	_	_	_	_
2	the	_	_	_	_	_	_	_	_
3	prognostic	_	_	_	_	_	_	_	_
4	and	_	_	_	_	_	_	_	_
5	therapeutic	_	_	_	_	_	_	_	_
6	value	_	_	_	_	_	_	_	_
7	of	_	_	_	_	_	_	_	_
8	stratifying	_	_	_	_	_	_	_	_
9	BCa	_	_	_	_	_	_	_	_
10	by	_	_	_	_	_	_	_	_
11	hormone	_	_	_	_	_	_	_	_
12	receptor	_	_	_	_	_	_	_	_
13	status	_	_	_	_	_	_	_	_
14	,	_	_	_	_	_	_	_	_
15	further	_	_	_	_	_	_	_	_
16	delineation	_	_	_	_	_	_	_	_
17	of	_	_	_	_	_	_	_	_
18	the	_	_	_	_	_	_	_	_
19	pathways	_	_	_	_	_	_	_	_
20	that	_	_	_	_	_	_	_	_
21	are	_	_	_	_	_	_	_	_
22	altered	_	_	_	_	_	_	_	_
23	between	_	_	_	_	_	_	_	_
24	these	_	_	_	_	_	_	_	_
25	subtypes	_	_	_	_	_	_	_	_
26	,	_	_	_	_	_	_	_	_
27	such	_	_	_	_	_	_	_	_
28	as	_	_	_	_	_	_	_	_
29	scOHC-LXR	_	_	_	_	_	_	_	_
30	signalling	_	_	_	_	_	_	_	_
31	,	_	_	_	_	_	_	_	_
32	may	_	_	_	_	_	_	_	_
33	help	_	_	_	_	_	_	_	_
34	advance	_	_	_	_	_	_	_	_
35	understanding	_	_	_	_	_	_	_	_
36	about	_	_	_	_	_	_	_	_
37	the	_	_	_	_	_	_	_	_
38	emerging	_	_	_	_	_	_	_	_
39	roles	_	_	_	_	_	_	_	_
40	of	_	_	_	_	_	_	_	_
41	cholesterol	_	_	_	_	_	_	_	_
42	metabolism	_	_	_	_	_	_	_	_
43	in	_	_	_	_	_	_	_	_
44	cancer	_	_	_	_	_	_	_	_
45	and	_	_	_	_	_	_	_	_
46	improve	_	_	_	_	_	_	_	_
47	outcomes	_	_	_	_	_	_	_	_
48	for	_	_	_	_	_	_	_	_
49	patients	_	_	_	_	_	_	_	_
50	.	_	_	_	_	_	_	_	_

